Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth-Reference-Cited by-同舟云学术

Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth

Published:2024-07-25 Issue:1 Volume:25 Page:
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Johnson Spenser S.¹,Liu Dijie²,Ewald Jordan T.¹,Robles-Planells Claudia²,Pulliam Casey¹,Christensen Keegan A.¹,Bayanbold Khaliunaa¹,Wels Brian R.³,Solst Shane R.¹,O’Dorisio M. Sue²,Menda Yusuf⁴,Spitz Douglas R.¹,Fath Melissa A.¹^ORCID

Affiliation:

1. Department of Radiation Oncology, Holden Comprehensive Cancer Center, Free Radical and Radiation Biology Program, University of Iowa Hospitals and Clinics, IA, USA

2. Department Pediatrics, University of Iowa Hospitals and Clinics, IA, USA

3. State Hygienic Laboratory, University of Iowa, IA, USA

4. Department of Radiology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, IA, USA

Funder

disclosed receipt of the following financial support for the researc

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2024.2382524

Reference54 articles.

1. Classification of pulmonary neuroendocrine tumors: new insights

2. Systemic treatment for lung carcinoids: from bench to bedside

3. Small-cell lung cancer

4. Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer

5. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities